Abstract：
There is much debate about continuing antipsychotic medication in patients who need it when they become pregnant because benefits must be weighed against potential teratogenic and malformation effects related to antipsychotics themselves. To address this, we conducted a systematic review on the PubMed, PsycINFO and CINHAL databases and the ClinicalTrials.gov register using the following strategy: (toxicity OR teratogenicity OR malformation* OR \"birth defect*\" OR \"congenital abnormality\" OR \"congenital abnormalities\" OR \"brain changes\" OR \"behavioral abnormalities\" OR \"behavioral abnormalities\") AND antipsychotic* AND (pregnancy OR pregnant OR lactation OR delivery OR prenatal OR perinatal OR post-natal OR puerperium) on September 27, 2023. We found 38 studies to be eligible. The oldest was published in 1976, while most articles were recent. Most studies concluded that the antipsychotics, especially the second-generation antipsychotics, were devoid of teratogenic potential, while few studies were inconclusive and recommended replication. Most authoritative articles were from the Boston area, where large databases were implemented to study the malformation potential of psychiatric drugs. Other reliable databases are from Northern European registers. Overall conclusions are that antipsychotics are no more related to malformations than the disorders themselves; most studies recommend that there are no reasons to discontinue antipsychotic medications in pregnancy.
摘要：
对于怀孕时需要继续服用抗精神病药物的患者，存在很多争论，因为必须权衡与抗精神病药物本身相关的潜在致畸和畸形作用。为了解决这个问题，我们对PubMed进行了系统的审查，使用以下策略的PsycINFO和CINHAL数据库和ClinicalTrials.gov注册：（毒性或致畸性或畸形*或“出生缺陷*”或“先天性异常”或“先天性异常”或“大脑异常”或“行为异常”或“行为异常”）和抗精神病药物*（妊娠或妊娠或哺乳期或产前或产后）2023年9月27日。我们发现38项研究符合资格。最古老的文章发表于1976年，而大多数文章都是最近发表的。大多数研究得出结论，抗精神病药，尤其是第二代抗精神病药，缺乏致畸潜力，虽然很少有研究没有定论并推荐复制。大多数权威文章来自波士顿地区，在那里实施了大型数据库来研究精神药物的畸形潜力。其他可靠的数据库来自北欧登记册。总体结论是，抗精神病药物与畸形的关系并不比疾病本身更多；大多数研究认为，没有理由在怀孕期间停用抗精神病药物。
